Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Not applicable
Started
2018-07-19
Last updated
2026-05-19
Condition(s) studied
Breast NeoplasmsNeoplasm Recurrence, Local
Investigational drug(s) / intervention(s)
Accelerated Partial Breast Irradiation
Accelerated Partial Breast Irradiation: Patients are irradiated to the region of tumour bed using intensity modulated radiation therapy (IMRT)
Study summary
This study is to evaluate the efficacy and toxicity of accelerated partial breast irradiation (ABPI) with intensity modulated radiation therapy (IMRT) in low-risk breast cancer treat with breast-conserving surgery.
Eligibility
Sex
FEMALE
Min age
45 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Life Expectation: \> 5 years
* Enrollment date no more than 12 weeks after breast-conserving surgery or no more than 8 weeks after adjuvant chemotherapy
* Histologically confirmed diagnosis of invasive ductal carcinoma (grade 1-2), or mucinous carcinoma, or papillary carcinoma, or tubular carcinoma, or medullary carcinoma: primary tumor ≤ 3.0cm in maximum diameter and pN0; or histologically confirmed DCIS: primary tumor ≤ 2.5cm in maximum diameter, low-medium grade
* Unifocal tumour (confirmed by diagnostic MRI)
* No lymphovascular invasion
* ER positive (defined as medium-strongly nuclear staining in \>1% of the cancer cells)
* Negative radial resection margins of \>= 2 mm
* Surgical clips placed in the tumor bed
* Written informed consent.
Exclusion Criteria:
* Stage Ⅱ-Ⅲ
* Multifocal tumors
* Histologically confirmed diagnosis of invasive ductal carcinoma (grade 3), invasive micropapillary carcinoma, carcinoma of lobular in situ, invasive lobular carcinoma
* Paget's disease of the nipple
* Underwent oncoplastic surgery of ipsilateral breast
* Underwent neoadjuvant chemotherapy or hormonal therapy
* Previous or simultaneous contralateral breast cancer
* Undergone ipsilateral chest wall radiotherapy
* Active collagen vascular disease.
Primary outcome measure(s)
locoregional control rate — 5 years ipsilateral breast and axilla nodal relapse rate
Trial sites (1)
Facility
City
Region
Status
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences
Beijing
Beijing Municipality
More Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.